… repeated dosing of glucagon-like peptide-2 (GLP-2) at 10 pm in postmenopausal women for
14 … , appeared to be unaffected by treatment with exogenous GLP-2, at least over 14 days. …

… injection of glucagon-like peptide-2 (GLP-2) at 10 pm in postmenopausal women results in a
… terminal propeptide (PINP), appeared to be unaffected by treatment with exogenous GLP-2. …

… We hypothesized that both GIP and GLP-2 alone and in combination would reduce the …
administered subcutaneously to postmenopausal women at bedtime. 2. Material and methods …

… plasma levels of glucagon-like peptide 1, glucagon-like peptide 2 and dipeptidyl-peptidase …
-diabetic postmenopausal women. We studied non-diabetic postmenopausal women with …

… glucagon-like peptide 2 (GLP-2), in bone remodeling has been recently studied in a variety
of clinical settings, including healthy volunteers, postmenopausal women and … GLP-2 is a 33 …

… postmenopausal women, a subcutaneous injection of the gastrointestinal hormone glucagon-like
peptide-2 (GLP-2) … GLP-2 is a 33-amino acid polypeptide, corresponding to amino acid …

… Regarding medications, postmenopausal women should be … -4i) or glucagon-like peptide-1
receptor agonists (GLP-1RA) … should be avoided in postmenopausal women with increased …

… In the current study we examined the effect of the GLP-1 RA Lira in the cardiometabolic … in
a postmenopausal model of PCOS. We tested the hypothesis that administration of the GLP-1 …

… 4 months of daily GLP-2 treatment significantly and dose dependently increased BMD in
postmenopausal women (29). It is unknown whether GLP-2 also decreases bone resorption in …

… reflect the risk of MetS in Korean women without a diagnosed disease. This was more distinct
in women who are postmenopausal, suggesting that GLP-1 may indeed be a useful early …